Novartis AG with ticker code (NVS) now have 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 108 and 100 and has a mean target at 104.4. Now with the previous closing price of 87.35 this indicates there is a potential upside of 19.5%. The day 50 moving average is 89.09 and the 200 day moving average is 86.07. The company has a market capitalisation of $192,773m. Company Website: https://www.novartis.com
The potential market cap would be $230,400m based on the market concensus.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
